Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | SRD5A2 | P31213 | 5/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | OGA | O60502 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6082644 | 1.00 | ALDH1A1 (0.46) | ALDH1A1LMNATP53ACHEPAX8 | |
| SCHEMBL17296082 | 0.84 | ACHE (0.48) | ALDH1A1LMNATP53ACHEPAX8 | |
| SCHEMBL15608176 | 0.83 | NFE2L2 (0.46) | ALDH1A1RAB9ANPC1 | |
| SCHEMBL13738308 | 0.83 | NFE2L2 (0.46) | ALDH1A1RAB9ANPC1 | |
| SCHEMBL19994676 | 0.81 | SRD5A2 (0.48) | ALDH1A1LMNATP53ACHEPAX8 | |
| SCHEMBL5341385 | 0.80 | ESR2 (0.43) | ALDH1A1LMNATP53GAAKMT2A | |
| SCHEMBL5341383 | 0.80 | ESR2 (0.43) | ALDH1A1LMNATP53GAAKMT2A | |
| SCHEMBL15667982 | 0.76 | HTT (0.34) | ALDH1A1LMNASRD5A2 | |
| SCHEMBL17602847 | 0.76 | HTT (0.34) | ALDH1A1LMNASRD5A2 | |
| SCHEMBL23887638 | 0.76 | SRD5A2 (0.43) | SRD5A2S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6984651-B2 | Piperidine amides as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA, COMPANY (US) | 2006-01-10 | — | — | US | disclosed |
| US-20040082790-A1 | Piperidine amides as modulators of chemokine receptor activity | DUNCIA JOHN V (US) | 2004-04-29 | — | — | US | disclosed |
| US-6638950-B2 | Antiasthmatics and antiallergens, treating autoimmune pathologies such as rheumatoid arthritis and atherosclerosis | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-10-28 | — | — | US | disclosed |
| EP-1296949-A2 | PIPERIDINE AMIDES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Bristol-Myers Squibb Pharma Company (US) | 2003-04-02 | — | — | EP | disclosed |
| US-20020156102-A1 | Piperidine amides as modulators of chemo kine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-10-24 | — | — | US | disclosed |
| WO-2001098268-A2 | PIPERIDINE AMIDES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156102-A1 | Piperidine amides as modulators of chemo kine receptor activity | CCR3, CCR1, ACKR3 | ALDH1A1 1698/4885LMNA 4487/4885TP53 4393/4885 |
| US-20040082790-A1 | Piperidine amides as modulators of chemokine receptor activity | CCR3, CCR1, CCL11 | ALDH1A1 722/4885LMNA 4607/4885TP53 4601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.